Items with tag "finance"

News

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing

15 November 2018, Ghent (Belgium) - V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals Camel-IDS is developing new radiopharm…

Read more

Mithra Women's Health presenting good news at CPHI conference

11 October 2018 - Mithra (Euronext Brussels: MITRA), a Liège-based company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference held yesterday…

Read more

Argenx raised over $300 million in their US public offering

18 September 2018 - Read the press release here. Argenx is a Belgian clinical-stage biotechnology company, developing differentiated antibody-based therapies for the treatment of severe autoim…

Read more

V-Bio Ventures participates in 22.5 million euros series B financing round of Horama

Ghent (Belgium), September 18th, 2018 - The Belgian life sciences venture fund V-Bio Ventures (www.v-bio.ventures) today announces that it joins the “Series B” financing round of Horama (www.horam…

Read more

Argenx announces launch of proposed public offering in the United States

Hot on the tail of Galapagos' successful public offering, Gent-based biotech Argenx is following suit! The biotech company, which is developing antibody-based therapies for cancer and autoimmune d…

Read more

Good News for Galapagos

Good News for Galapagos

It has been a huge month for Galapagos, with press releases issued in rapid succession. The news is all positive; the company has, in a very short amount of time, launched their initial public off…

Read more

Confo Therapeutics is awarded a EUR 1M grant to increase its screening capabilities

Confo Therapeutics announced today that it has received a €1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the…

Read more

Sanofi acquires Ablynx for €3.9 billion

Sanofi and Ablynx entered into a definitive agreement under which Sanofi will offer to acquire all of the outstanding ordinary shares, including shares represented by American Depositary Shares (A…

Read more

iTeos Therapeutics Granted EUR 7.5 Million Non-Dilutive Funding by the Walloon Region

iTeos Therapeutics SA, announced that it has been granted EUR 7.5 million in non-dilutive funding to support the clinical development of its lead anti-cancer drug. The funding has been approved on…

Read more

Mithra Signs Deal with Fuji Pharma for Donesta in Asia

Mithra, a company specialized in Women’s Health, announces that it has signed an exclusive License and Supply Agreement (LSA) with Fuji Pharma, the leader in Women’s Health in Japan, for the comme…

Read more

9.36 million euros for the Bio Base Europe Pilot Plant

ERDF Flanders and Bio Base Europe Pilot Plant (BBEPP) signed an agreement for an investment of €9,36 million within the framework of the IMPACT project. This investment is financed by the European…

Read more

argenx raises $100 million with NASDAQ IPO

With its Nasdaq debut, argenx raises $100 million, a significantly greater amount than the $60 million previously planned.

Read more

Novartis takes license on Celyad's allogeneic CAR T cells

Celyad, a leader in the discovery and development of cell therapies, today announced a non-exclusive license agreement with Novartis for Celyad’s US patents for the production of allogeneic CAR T …

Read more

Galapagos raises $338 million gross proceeds in a US public offering

Galapagos announced today the pricing of its U.S. public offering totaling $338 million gross proceeds of 3,750,000 new ordinary shares in the form of American Depositary Shares ("ADSs") at $90 pe…

Read more

argenx receives first preclinical milestone payment in AbbVie collaboration

ARGX-115, an antibody targeting to inhibit the release of TGF-beta from regulatory T-cells in an innovative way, reaches its first preclinical milestone. This triggers a $10 million payment from d…

Read more

Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis and overtreatment of men at risk of prostate cancer…

Read more

Galapagos doses first psoriatic arthritis patient with filgotinib

First dosing triggers $10 million milestone payment from Gilead

Read more

Ogeda acquired by Astellas Pharma for 800m

The japanese pharma enterprise Astellas has come to an agreement with Belgian biotech Ogeda, specialised in the development of small molecules targeting GPCR's.

Read more

EU-LIFE calls for an increased European Research Council budget

EU-LIFE, the alliance of European research centres in life sciences, urges politicians to unequivocally support the ERC by raising its budget in FP9 and endorsing its guiding principles. 

Read more

Argenx files for U.S. stock listing

argenx, the llama antibodies developer looking to treat severe autoimmune diseases and cancer, announced today that it has confidentially submitted a draft registration statement on Form F-1 to th…

Read more

argenx announces extension of therapeutic antibody alliance with Shire

Llama antibody developer for immune diseases and cancer argenx has announced the extension of its strategic partnership with Shire plc to advance the discovery and development of novel human thera…

Read more

Four times more funds for VIB

The Flemish Government will increase the annual support for the VIB from 15 million to 59 million per year. "The VIB is the catalyst of the Flemish biotechnology sector. It's an excellent referenc…

Read more

MITHRA GRANTED EUR 1.9 MILLION IN NON-DILUTIVE FUNDING

Women’s health expert Mithra Pharmaceuticals today announces that it has been granted EUR 1.9 million in non-dilutive funding from the Walloon Region. The grant follows a decision by the region's …

Read more

Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding

Confo Therapeutics is awarded EUR 2.6M in non-dilutive funding for the discovery of new fibrosis treatments and for expanding the use of its unique Confo® technology

Read more

ADx NeuroSciences receives 850.000 EUR support from Flemish Government for tracking brain disorders

Brain injuries, dementia and other neurological problems are often noticed too late. The damage is irrevocable. ADX Neurosciences S.A. is committed to developing biomarkers that can detect, with a…

Read more

Johnson & Johnson acquires Actelion

After weeks of rumors, the news was finally announced this morning. J&J is to buy Europes largest biotech company for a whopping $30 billion. The R&D division of the Swiss company will be spun out…

Read more

OCTIMET Oncology NV secures over EUR 11 million to develop its highly selective MET kinase inhibitors

Octimet Oncology announced today that it has completed its series A investment round. The cancer start-up was able to secure €11.3 million from an investment syndicate led by V-Bio Ventures and Fu…

Read more

PharmaFluidics raises 2.7 million euro to commercialize novel micro-chip device

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, announced today that it has raised 2.7 million euro of additional funding.

Read more

ViroVet successfully raises €5 million in series A funding

ViroVet NV, a leading Belgian biopharmaceutical company active in the development of innovative vaccines and antiviral drugs for livestock, announces that it has successfully concluded the first c…

Read more

Promethera Biosciences and LifeLiver Sign Alliance

Promethera Biosciences SA, the world-leading cell therapy and regenerative medicine company targeting liver diseases, and LifeLiver, the Korean leader in the field of treatment of severe liver dis…

Read more

Bone Therapeutics Granted EUR 2.3 Million by the Walloon Region

Bone cell therapy company Bone Therapeutics receives 2.3 million in funding from the Wallonian Government.

Read more

Ablynx to present at the 35th annual J.P. Morgan Healthcare Conference

Ablynx will present at the 35th Annual J.P. Morgan Healthcare Conference on Thursday 12 January, at 1.30 am CET (Wednesday 11 January 2017 at 4:30 p.m. PST).

Read more

$12 million for Univercells's vaccines

The Gosselies-based Univercells received a $12 million grant from the Bill & Melinda Gates Foundation for the development of a breakthrough vaccine manufacturing platform. The objective is to radi…

Read more

IPO of Tigenix finally a fact!

TiGenix will issue 55 million new shares at the current share price, accounting for a capital injection of 50 million euros.

Read more

V-Bio Ventures announces the final closing of its first fund, raises over €75 million

After an initial closing in November 2015, V-Bio Ventures now expands its already impressive investor roster and establishes itself as one of Europe’s largest early stage life sciences investment …

Read more

Ablynx quickly delivers on Novo Nordisk collaboration

Almost exactly one year after Ablynx announced its collaboration with Novo Nordisk, their research project for the Danish pharma giant has reached a discovery milestone. Ablynx is developing a mul…

Read more

Biocartis' mini-lab soon available on US market

Biocartis granted rights to Thermo Fisher Scientific to distribute its rapid and fully automated molecular diagnostics Idylla platform in the US, including its accompanying assays, with a first fo…

Read more

60 million euro for KU Leuven's Centre for Drug Design and Discovery

The Centre for Drug Design & Discovery (CD3) has launched a 60 million euro fund to turn innovative biomedical research of academic institutions and small companies into drugs that improve and ext…

Read more

Tigenix' cash position gets stronger and stronger

Tigenix received in July a contribution of 25 million euros from Takeda, which doubled its cash position. The Japanese company wants to market Cx601, Tigenix' flagship product. Cx601 is a trea…

Read more

Only one stop more for Galapagos to market filgotinib

Galapagos initiates the third and final test phase for filgotinib, a candidate drug to treat rheumatoid arthritis, a potential flagship product. They do this in collaboration with US partner Gilea…

Read more

European money for Belgian science!

Can snake venom help to cure diabetes? Can you charge an electric car while driving? Can we make more people play football and hence reduce heart disease? And is pork healthier if we feed the anim…

Read more

TiGenix inks massive deal with Takeda

Today cell therapy specialist TiGenix has disclosed a new deal with the Japanese pharmaceutical giant Takeda. The agreement allows Takeda the rights to license, develop and sell TiGenix’ Cx601 glo…

Read more

New US adventure for ThromboGenics' JETREA?

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today announces that the Office of Biotechnology Products of t…

Read more

Fresh money for llama biotech

Ablynx and Argen-X, two Ghent based biopharmaceutical companies, who develop drugs based on llama antibodies, easily obtained new capital from investors. ArgenX, active in the field of cancer …

Read more

Patent discussion knocks down UCB shares

Investors aren’t pleased with the news that UCB’s patent on its epilepsy medicine Vimpat is under assault again. The company’s shares dropped 6% when it was revealed that the US generic pharmaceut…

Read more

Japan pledges $130M to infectious disease fund

The Japanese government will invest an additional $130 million in the The Global Heath Innovative Technology (GHIT) Fund, which supports R&D on infectious diseases including malaria, tuberculosis,…

Read more

23,5 million euro for a cutting-edge allergy treatment

ASIT Biotech, a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, anno…

Read more

Wave & Pfizer begin metabolic disease collaboration

Wave Life Sciences Ltd. (NASDAQ:WVE) and Pfizer Inc. (NYSE:PFE) partnered to design and develop stereopure nucleic acid therapeutics for metabolic diseases. The partners will investigate therapies…

Read more

CRISPR company Intellia prices IPO

Gene editing company Intellia Therapeutics Inc. (NASDAQ:NTLA) raised $108 million on Thursday through the sale of 6 million shares at $18 in an IPO underwritten by Credit Suisse, Jefferies, Leerin…

Read more

Gene therapy play Orchard raises 30.7 million

Orchard Therapeutics (London, U.K.) raised $30.7 million in a series A round to develop ex vivo autologous hematopoietic stem cell gene therapies for primary immune deficiencies, metabolic disease…

Read more

Biogen to spin off hemophilia business

Biogen Inc. (NASDAQ:BIIB) said it plans to spin off its hemophilia business into a separate public company by early 2017. It intends to distribute shares in the still-unnamed company to Biogen sto…

Read more

5AM incubator spinout Homology raises $43.5M

Gene editing company Homology Medicines Inc. spun out of 5AM Ventures' incubator with a $43.5 million series A round led by 5AM and Arch Venture Partners. Temasek, Deerfield and Arch Overage Fund …

Read more


 Hope for cystic fibrosis patients

Galapagos NV and AbbVie announced that the companies have expanded their collaboration focused on the discovery, development and commercialization of therapy options for cystic fibrosis (CF). In p…

Read more

36 million euros for neurostimulation of spinal cord

The Swiss-Dutch company G-therapeutics, a spin-off from École Polytechnique Fédérale de Lausanne (EPFL), has announced that it received €36 million to develop and bring a realistic therapeutic sol…

Read more

Boehringer Ingelheim starts clinical development of second Ablynx nanobody

Nanobody producer Ablynx has received an €8 million milestone payment from longtime partner Boehringer Ingelheim. The German pharmaceutical heavyweight has started a phase I clinical trial with an…

Read more

Argen-X lands AbbVie

Argen-X starts a collaboration with the global biopharmaceutical company AbbVie to develop and commercialize its novel immuno-oncology drug candidate, ARGX-115. ARGX-115 is  a preclinical-stage hu…

Read more

ADx NeuroSciences shifts into higher gear

Plenty of good news for ADx NeuroSciences. Today, the Ghent-based Alzheimer specialist has announced the end of its third capital round as well as a new agreement with their American partner Quant…

Read more

Q-Biologicals becomes part of Amatsigroup

French pharmaceutical conglomerate Amatsigroup has announced its acquisition of Q-Biologicals. Q-Biologicals was founded in 2011 as a VIB/UGent spin-off by several Innogenetics veterans and provid…

Read more

Argenx attracts American investors

Ghent-based antibody producer Argenx has caught the eye of American investors. Today, Argenx announced that one of U.S.’ largest investment companies, Federated Investors, is investing 16 million …

Read more

2 million euros for animal scanner

The Belgian startup Molecubes received 1.9 million euro from different investors for the commercialization of a compact scanner for animals. Molecubes, a spin-off from the University of Ghent…

Read more

Tigenix goes American

Since 2007, Tigenix is listed on the Euronext Brussels stock exchange. Now, the Leuven-based company wants to expand its reach and has announced a request for registration on the American Nasdaq s…

Read more

Galapagos finally managed to close long awaited deal

Earlier this year, AbbVie turned down its deal with Galapagos for co-development and commercializiation of the drug filgotinib for treatment of reumathoid arthritis. Last week, Galapagos announced…

Read more

IBA: Major breakthrough for proton therapy

With profits of 112%, IBA is one of the star companies of 2015. More and more hospitals acknowledge the enormous benefits of proton therapy to fight cancer. You do not often encounter a CEO th…

Read more

Bill & Melinda Gates Foundation fund University of Antwerp’s polio research

Gates wants to eradicate polio with the help of UAntwerpen. In the Western world, polio is no longer existent since a couple of decades. However, it still makes victims in developing countries, al…

Read more

Device for 3D hologram images of cells

Ovizio, launched in 2009 as spin-off from the ULB, develops ultra specialized microscopes allowing creation of a hologram-like 3D image of biological cells. The device is ideal to follow up on the…

Read more

Finnish biotech settles in Belgium

Belgium continues to attract the attention of life science companies worldwide. This time, it's the High North that has taken interest in our unique biotech ecosystem. Ozics, a Finland-based biome…

Read more

Jackpot for TiGenix' sepsis research

The biotech company TiGenix gets financial support in his search for a cure for severe sepsis due to pneumonia. The European Commission granted the Leuven-based company and its partners an amount …

Read more

€1.4 million for liquid biopsy to detect cancer

The IWT (Flemish Agency for Innovation by Science and Technology) granted 1,4 million euros to Biocartis to support the development of a liquid biopsy diagnostic test for melanoma and colorectal c…

Read more

Biogazelle to aid Isis pharma in the search for lncRNA disease targets

Today UGent spin-off company Biogazelle announced their collaboration with Isis pharmaceuticals. Being the leading company in the development of pharmaceutical products directed towards RNA target…

Read more

Apitope receives 12 million euros from Wales

The Belgian-British biotech company Apitope, which started as a spin-off of the Hasselt University in Diepenbeek, gets 12 million euros from an investor in Wales. It concerns the Wales Life Scienc…

Read more

Dutch company acquired by MDxHealth

The Dutch biotech company NovioGendix is acquired by the Belgian company MDxHealth. MDxHealth will pay $ 8.8 million (€ 7.8 million) for the Nijmegen-based company. NovioGendix is a spin-off of th…

Read more

Biocartis confirms Idylla sales and patient value

The first half year results of Biocartis confirm a successful expansion of Idylla™, Biocartis’ fully automated molecular diagnostics system. 114 instruments (up to June 30, 2015) have been sold to…

Read more

Roche acquires Biocartis’ competitor

Roche has paid 190 million dollar for the acquisition of GeneWEAVE (Los Gatos, CA), an American company that specializes in molecular diagnostics. GeneWEAVE’s shareholders even can receive 235 mil…

Read more

Free support and subsidies available to develop talents within your company!

Belgian life sciences companies are eligible for free training, subsidies for internal courses and consultancy cheques to pay an external HR-consultant. Co-valent, the training fund for the life s…

Read more

Pharma is not interested in 7 million euros

Since the end of 2014, pharmaceutical companies have the possibility to submit an application to the Riziv/Inami to obtain funds to make new medicines accessible faster for patients, for diseases …

Read more

New independent platform to advise investors: Researchpool

Two former employees of Euronext have established a platform for the dissemination of research. A part of the reports is for free. Right now, Researchpool has one Belgian writer: the independe…

Read more

New kid on the biotech block: Confo Therapeutics

Confo Therapeutics, is the new spin-off of VIB and Vrije Universiteit Brussel. A consortium led by Capricorn Health-Tech Fund with the participation of Qbic and SOFI contributed € 3 million in the…

Read more

Undizzy you by crowdfunding “Dizzy Me”

Tania Stadsbader, a patient who suffered more than 10 years from dizziness, and Floris Wuyts, professor in Physics at UA, head of AUREA (Antwerps Universitair Researchcentrum voor Evenwicht) and A…

Read more

“Give Life a Chance”: new research fund for neuroendocrine tumors

The University of Hasselt, the Jessa Hospital and the East Limburg Hospital will conduct research on neuroendocrine tumors (NET), a rare and aggressive form of cancer, with help from “Give Life a …

Read more

Bone Therapeutics grows both locally and internationally to become a champion of bone regenerative medicine

Walloon bone cell therapy company, Bone Therapeutics (BOTHE), is moving into their new headquarters in Gosselies. The new 3000m² facility is part of a larger project, the Walloon Cell Therapy Plat…

Read more

Take your own venture and make it a business case

The Executive Master of Business Innovation & Entrepreneurship in Life Sciences & Health (MBI Life Sciences and Health) is a unique ‘hands-on’ MBA program to accelerate life sciences ventures or b…

Read more

Government should invest in clinical trials

The government should invest each year a minimum of 10 to 15 million euros in publicly funded clinical trial according to the Belgian Health Care Knowledge Centre (KCE). Not all health care proble…

Read more

New biotech fund for Belgian companies!

Désiré Collen launched a new biotech fund, Fund+. The founder of Thrombogenics collected money from Urbain Vandeurzen, AB InBev billionaire Arnaud de Pret and government funds. The ambition of Dés…

Read more

MiDiagnostics develops disposable chip for blood self-testing

MiDiagnostics is a new startup that will make disposable chips to test your own blood and saliva. Only 15 minutes after the test, you will be able to read on your smartphone whether you have to ta…

Read more

arGEN-x receives €1.5 million for enhancement of therapeutic antibodies

In early May 2015, arGEN-X N.V. (ARGX) received a €1.5 million grant from the Flemish IWT (the government agency for Innovation by Science and Technology). arGEN-X creates novel therapeutic antibo…

Read more

AbbVie as a shareholder of Galapagos

About AbbVie as a shareholder of Galapagos, Jan De Kerpel says in De Tijd: “It gives a dual message to investors considering to subscribe to the capital increase. With $ 30 million, AbbVie has alr…

Read more

Silicon Valley’s Agilent Technologies buys Cartagenia

Cartagenia, established in 2008 as a spin-off from the University of Leuven, has been taken over by the American company, Agilent Technologies. Cartagenia develops analytical software for molecula…

Read more

Government incentives financially benefit startups

The Cabinet has set the fiscal conditions concerning tax shelters and crowdfunding for start-ups. The government wants to give start-ups a helping hand with these incentives. Although the regulati…

Read more

New biotech incubator in Ghent

Rudi Mariën, founder of former Innogenetics, and investor in multiple Flemish biotech companies and projects, is building a new business center which can house up to a dozen biotech startups “The …

Read more

Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gathered 100 million euros with an offer of 8,7 million …

Read more

Trinean wins 25.000 euro for disposables production

Trinean won the “Time for a Boost 2015” competition organized by Test and Measurement Solutions. CEO Kurt Hensen handed a cheque of 25 000 euro to the Ghent University spin-off. Trinean develo…

Read more

Biotech also benefits your financial health

In the US it is known for a long time: biotech is of vital importance and there is money to be made! Rudi Van den Eynde from Candriam comments: “In 2000, biotech was considered as a promising but …

Read more

Galapagos reports encouraging initial results in clinical trial on reuma

Galapagos NV announced that the selective JAK1 inhibitor filgotinib improved the symptoms of active rheumatoid arthritis and met key efficacy endpoints after 12 weeks of treatment. This Phase 2B s…

Read more

Better decision making with VIGOR

The VIGOR Unit, a new spin-off of the University of Ghent, will help business leaders and policy makers take effective decisions on the basis of scientific insights and data. The focus of the foun…

Read more

Biocartis aiming for 100 to 125 million

In the second week of the Easter holidays, Biocartis will launch its IPO. According to experts it aims at raising 100-125 million euros, double what was raised privately in September. Since its fo…

Read more

Sabine Sagaert to lead Cargill's malt division globally

US agricultural and food giant Cargill has appointed Sabine Sagaert as head of its malt division worldwide. Up till now, Sagaert has been responsible for the malt division in Europe.  Starting on …

Read more

Cancer Specialist IBA shines after new contract in Florida

IBA (Louvain-La-Neuve), a specialist in proton therapy for cancer treatment, saw it’s stock rise from 7.3% to 23.90 euros. The Walloon company netted an American contract of 74 million euros in Fl…

Read more

Galapagos thinks big

Galapagos, the Mechelen biotech company, quit its inflammation alliance with Janssen under mutual agreement. Galapagos regained the proprietary rights of GLPG1205 and GLPG1690, two molecules under…

Read more

Costs for treatment of HIV

The University of Hasselt and the AIDS Reference Centre of Ghent University Hospital calculated that the treatment for people infected with HIV in Belgium costs 1027.5 euro per patient per month, …

Read more

Orgenesis adopts stem cells with MaSTherCell

The American company Orgenesis obtained MaSTherCell (Gosselies) for $24.6 million. Enterpreneur Hugues Bultot’s MaSTherCell specializes in the production of stem cells for therapeutic purposes s…

Read more

Mithra to become the new Omega Pharma?

Businessman Marc Coucke has invested 40 million euros in the Liège pharmaceutical company Mithra. Coucke is now the second largest shareholder, behind his Walloon counterpart, CEO François Fornier…

Read more

Insights

argenx signs billion-dollar deal with Janssen

argenx signs billion-dollar deal with Janssen

Another Belgian biotech on the up and up: argenx just closed a billion-dollar deal with Janssen Pharmaceutica for their antibody cusatuzumab. Under the terms of the agreement, Janssen will pay arg…

Read more

Lessons in Herding Cats: Business Development for Life Sciences Companies

Lessons in Herding Cats: Business Development for Life Sciences Companies

Business development challenges can make or break a company in any industry. For a life sciences company, overcoming the added hurdles inherent in the field makes success even more challenging. Dr…

Read more

Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos and MorphoSys to receive up to EUR 850mil in deal with Novartis

Galapagos (Belgium) and MorphoSys (Germany) recently announced that they have entered into an exclusive global license agreement with Novartis. The Swiss big-pharma partner has acquired the rights…

Read more

CD3 as co-creator of drugs with academia and pharma

CD3 as co-creator of drugs with academia and pharma

The Center for Drug Design and Discovery (CD3), based in Leuven, bridges the gap between innovative biomedical research emerging from academic institutions or SMEs and pharmaceutical companies. Th…

Read more

After Ablynx, is an acquisition of Galapagos next?

After Ablynx, is an acquisition of Galapagos next?

The Gent biotech company Ablynx has been acquired by pharmaceutical giant Sanofi for 3.9 billion euros. The French Sanofi beat the Danish company Novo Nordisk to the deal after a much higher offer…

Read more

Reversed Brexit: £250 million for Bart De Strooper's dementia research

Reversed Brexit: £250 million for Bart De Strooper's dementia research

The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The institute hopes to assemble top-notch neurodegenerative research from around the countr…

Read more

CMAST: Bringing ideas from a risky early stage to a viable healthcare solution

CMAST: Bringing ideas from a risky early stage to a viable healthcare solution

CMAST knows that much more than good science is needed to create innovative healthcare solutions that will have an impact on society. The company aims to accelerate the advancement of promising pr…

Read more

Flanders Innovation and Enterpreneurship hands out over 500 million euros

Flanders Innovation and Enterpreneurship hands out over 500 million euros

Startup companies can get funding from the Flemish government for their R&D activities. Recently, the responsible agency was reformed and is now known as Flanders Innovation and Enterpreneurship (…

Read more

Biotech financials: Part 2 — the Belgian stock market

Biotech financials: Part 2 — the Belgian stock market

Biotech is a sector that involves considerable risk: The amount of capital required is huge, and any clinical research program has a fairly large chance of failure at any stage of the development …

Read more

How to explain the Galapagos peak

How to explain the Galapagos peak

Since mid-September, Galapagos’ shares have been rising explosively and reaching new all-time highs. This was curious, since the company has not made any major announcements or released any new in…

Read more

Biotech financials: Part 1 - The bigger the company, the bigger the money

Biotech financials: Part 1 - The bigger the company, the bigger the money

Belgium is internationally known for its flourishing biotech scene. Companies such as Galapagos and Ablynx are now synonymous with innovation and high-quality research, assets that are, in turn, w…

Read more

All in on cancer immunotherapy

All in on cancer immunotherapy

Founded in 2011, iTeos Therapeutics began its activities at the end of 2012. Active in the field of cancer immunotherapy, the company develops innovative drugs by focusing on the tumor microenviro…

Read more

From Belgium to NYC and starting a 'super sniffer’ company

From Belgium to NYC and starting a 'super sniffer’ company

Charlotte D’Hulst left Belgium for a postdoc in NYC. Today she has two kids and lives in Brooklyn. Oh, and she founded a biotech company, MouSensor, LLC. Hard to resist the entrepreneurial buzz in…

Read more

The Year of Biocartis

The Year of Biocartis

2015 was a truly eventful year for Biocartis. It was marked by many transitions, which some see as a prelude to the company becoming a globally active market leader. Biocartis saw the source of it…

Read more

Why Bernard Coulie left Belgium for the US

Why Bernard Coulie left Belgium for the US

Bernard Coulie studied medicine, worked for Johnson & Johnson, obtained an MBA, and co-founded ActoGeniX, which was later acquired by Intrexon. Coulie now works as CEO of Pliant Therapeutics, for …

Read more

Simulate your trials and save time and money!

Simulate your trials and save time and money!

Engineering simulation is the next big thing in medical development. It can be used to design, rethink and optimize devices before going into clinical trials. These simulations can also be used as…

Read more

New money for life sciences startups!

New money for life sciences startups!

While many investors shy away from financing early-stage companies, the VIB took the bold initiative to set up a new fund dedicated to investing in start-ups and young life sciences companies. …

Read more

Belgium’s investment market amongst the best in Europe

Belgium’s investment market amongst the best in Europe

Investing in biotech requires big money; several financing rounds are necessary to allow a company to fully develop itself. Early stage financing is more risky than investing in more mature compan…

Read more

The Fournier-Majoie Foundation: guiding cancer research to clinical application

The Fournier-Majoie Foundation: guiding cancer research to clinical application

At 77 years of age, Bernard Majoie is as active as ever. As founder of the Fournier-Majoie Foundation, he dedicates his time to the battle against cancer. His philanthropic foundation provides fun…

Read more

How (not) to invest in biotech - Rudi Mariën

How (not) to invest in biotech - Rudi Mariën

Rudi Mariën is without doubt a heavyweight in the Belgian biotechnology industry. After establishing his flourishing clinical lab BARC, he co-founded Innogenetics. Financing one of the first Belgi…

Read more

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Better and cheaper treatment of Crohn’s disease: BIOCYCLE

Crohn’s disease is a type of inflammatory bowel disease, which is becoming increasingly prevalent in the developing world. It’s an immune-related disease, causing abdominal pain, diarrhea, fever a…

Read more

Reindustrialization of Europe with a €3.7 billion investment in green industries

Reindustrialization of Europe with a €3.7 billion investment in green industries

The bioeconomy uses renewable resources instead of fossil resources. Biorefineries play a central role in intelligently converting biomass and waste, via efficient and innovative technologies, int…

Read more

Disposable bioreactors: a cost-saving innovation

Disposable bioreactors: a cost-saving innovation

Companies who manufacture biotechnology products such as monoclonal antibodies, therapeutic proteins and vaccines, produce a wide range of products in small amounts. They need to switch quickly be…

Read more

IPO Bone Therapeutics yields 32.2 million euro

IPO Bone Therapeutics yields 32.2 million euro

Bone Therapeutics – a Walloon cell therapy company specialized in bone fracture repair and prevention – shifts up a gear and raises 32.2 million euro in a 2.5 times oversubscribed successful IPO o…

Read more

VC Views

Why start-ups can become mega companies in the pharma sector

Why start-ups can become mega companies in the pharma sector

In a previous BioVox article, we analyzed the steps needed for a life sciences start-up to turn into a fully integrated, commercial stage biotech company. For this to happen, the hurdles that need…

Read more

Biotechs and subsidies - a fraught relationship

Biotechs and subsidies - a fraught relationship

The ambition of any CEO heading a biotech start-up is to develop a new product and to reach patients quickly. However, drug development comes with long development timelines, making Biotech a capi…

Read more

Acquisitions of Biotech companies: a good or a bad thing?

Acquisitions of Biotech companies: a good or a bad thing?

When on the 8th January 2018 the news travelled that Novo Nordisk made a €2.6bn bid for Belgium’s Ablynx, only to be leapfrogged a few weeks later by the € 3.9bn Sanofi bid, we immediately picture…

Read more

How to build a “European Amgen”

How to build a “European Amgen”

There are still very few large European biotech companies to compete with the Amgens and Gileads of the world.  Only a handful of European biotech companies have managed to stay independent, grow,…

Read more

Is innovation killing the pharmaceutical industry?

Is innovation killing the pharmaceutical industry?

In the past few years, the speed at which new drugs have been coming to the market has accelerated significantly [1]. This means there is a lot more competition than before, greatly affecting the …

Read more

Belgium vs Germany in the Life Sciences start-up championship

Belgium vs Germany in the Life Sciences start-up championship

Germany is one of the leading industrial nations in the world and has 8x more inhabitants than Belgium. However, when it comes to investments in early startups and early stage funds in life scienc…

Read more

How Aphea.Bio managed to gather the funds to transcend from academia to industry

How Aphea.Bio managed to gather the funds to transcend from academia to industry

Aphea.Bio is an agriculture startup, originating from the VIB and flourishing underneath the wings of V-Bio Ventures. Steven Vandenabeele (CTO at Aphea.Bio and previously working at BASF-CropDesig…

Read more

The leap from academia to industry

The leap from academia to industry

The earlier in development, the greater the risk. It’s an unspoken law in biotech that makes valorizing promising academic projects difficult to fund. Venture Capitalists (VCs) specialized in earl…

Read more

Strengthening communication in biotech companies

Strengthening communication in biotech companies

Many biotech management teams fail to reach out to investors in a clear and appealing way.

Read more

Curing all diseases in the next 20 years: the new hype amongst billionaires?

Curing all diseases in the next 20 years: the new hype amongst billionaires?

Despite the initial intent of charitable foundations to be not-for-profit, some of them tend to morph into organizations with bigger aspirations.

Read more

Investing in European biotech faced with many challenges

Investing in European biotech faced with many challenges

Investing in biotech companies is a capital-intensive and risky business, and it’s no secret that more money and less risk-averse investors are available in the US than in Europe. To keep innovati…

Read more

Grail: A billion-dollar gamble?

Grail: A billion-dollar gamble?

Grail has vowed to change the field of cancer diagnostics via simple blood tests and ctDNA analysis. Their Big Data approach, in which the company will build an atlas of DNA found in the blood, co…

Read more

V-Bio Ventures spends big money in life sciences

V-Bio Ventures spends big money in life sciences

Only one year after its inception, the life science investment fund V-Bio Ventures made its first investments in three companies and announced the final closing of their first fund. Time to discus…

Read more

Biotech through the eyes of a financial analyst

Biotech through the eyes of a financial analyst

Ward Capoen studied biology and subsequently obtained a PhD in biotechnology at Ghent University. He worked as a postdoctoral fellow at the John Innes Centre in the UK, to continue his career as a…

Read more

Inside a life sciences fund: V-Bio Ventures

Inside a life sciences fund: V-Bio Ventures

V-Bio Ventures, the new Belgian fund for life sciences startups, is currently being managed by Christina Takke and Willem Broekaert. They both have a life sciences background and gained experience…

Read more

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

V-Bio Ventures XpandInnovation UGent KU Leuven Itera Life Science Flanders.bio Biowin Turnstone GSK Janssen

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.